- Home
- BEEM vs SCYX Comparison
BEEM vs SCYX Comparison
Compare BEEM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- SCYX
- Stock Information
- Founded
- BEEM 2006
- SCYX 1999
- Country
- BEEM United States
- SCYX United States
- Employees
- BEEM N/A
- SCYX N/A
- Industry
- BEEM Semiconductors
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- SCYX Health Care
- Exchange
- BEEM Nasdaq
- SCYX Nasdaq
- Market Cap
- BEEM 35.5M
- SCYX 34.9M
- IPO Year
- BEEM N/A
- SCYX 2014
- Fundamental
- Price
- BEEM $2.35
- SCYX $1.12
- Analyst Decision
- BEEM Strong Buy
- SCYX
- Analyst Count
- BEEM 4
- SCYX 0
- Target Price
- BEEM $5.33
- SCYX N/A
- AVG Volume (30 Days)
- BEEM 190.8K
- SCYX 199.8K
- Earning Date
- BEEM 11-13-2025
- SCYX 11-05-2025
- Dividend Yield
- BEEM N/A
- SCYX N/A
- EPS Growth
- BEEM N/A
- SCYX N/A
- EPS
- BEEM N/A
- SCYX N/A
- Revenue
- BEEM $33,362,000.00
- SCYX $3,257,000.00
- Revenue This Year
- BEEM N/A
- SCYX $422.61
- Revenue Next Year
- BEEM $45.38
- SCYX $240.56
- P/E Ratio
- BEEM N/A
- SCYX N/A
- Revenue Growth
- BEEM N/A
- SCYX N/A
- 52 Week Low
- BEEM $1.33
- SCYX $0.66
- 52 Week High
- BEEM $5.57
- SCYX $1.66
- Technical
- Relative Strength Index (RSI)
- BEEM 44.39
- SCYX 74.20
- Support Level
- BEEM $2.41
- SCYX $0.81
- Resistance Level
- BEEM $2.63
- SCYX $0.88
- Average True Range (ATR)
- BEEM 0.17
- SCYX 0.07
- MACD
- BEEM -0.05
- SCYX 0.03
- Stochastic Oscillator
- BEEM 12.20
- SCYX 62.33
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.